Update on the Pharmacologic Agents for Dyslipidemia.
10.4093/jkd.2015.16.4.269
- Author:
Sang Hak LEE
1
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac
- Publication Type:Review
- Keywords:
Cholesterol ester transfer proteins;
Ezetimibe;
Fibric acids;
Human PCSK9 protein;
Hydroxymethylglutaryl-CoA reductase inhibitors;
Niacin;
Omega-3 fatty acids
- MeSH:
Cholesterol Ester Transfer Proteins;
Dyslipidemias*;
Fatty Acids, Omega-3;
Fibric Acids;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Niacin;
Prescriptions;
Proprotein Convertases;
Ezetimibe
- From:Journal of Korean Diabetes
2015;16(4):269-275
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
